Grifois (GRFS)

• Market cap: $6.38B
• 1 day: 2.29%
• 5 days: -1.78%
• 1 month: -5.92%
• 3 months: -12.43%
• 6 months: 34.82%
• Year to date: 24.27%
• 1 year: 7.83%
• 5 years: -45.59%
• 10 years: -46.76%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Employees: 23,800